Challenges and Emerging Strategies for Aromatase Inhibitors in Postmenopausal Breast Cancer Treatment

Anuradha G. More¹*, Dhanashri P. Garud²

¹P.E. Society’s Modern College of Pharmacy, Nigdi, Pune - 411044, Maharashtra, India.

²P.E. Society’s Modern College of Pharmacy, SPPU, Pune - 411044, Maharashtra, India.

*Corresponding Author E-mail: anuradhagmore2011@gmail.com

ABSTRACT:

Breast cancer is the most prevalent solid malignant tumor worldwide, affecting 2.26 million women, with approximately 685,000 deaths from the disease, as estimated on an annual basis by the World Health Organization.  About 60-80% of invasive breast cancer in postmenopausal women are estrogen or hormone-receptor-positive breast tumors. Endocrine therapy is a cornerstone for treating hormone receptor-positive breast cancer and includes selective estrogen receptor modulators like Tamoxifen and aromatase inhibitors. Besides the therapeutic effects of hormonal therapy, challenges such as osteoporosis induced by aromatase inhibitors, drug resistance, and recurrence complicate the management of breast cancer. Consequently, there is a significant demand for practical approaches to overcome resistance to endocrine therapy and prevent breast cancer metastasis. This article focuses on therapy for estrogen-positive breast cancer and its adverse impact on patient quality of life. It also examines strategies to reduce side effects by combining natural sources with nanocarriers to enhance therapeutic effects and minimize side effects. It also reviews ongoing research aimed at improving outcomes for patients with hormone-positive breast cancer.

KEYWORDS: Breast Cancer, Estrogen, Aromatase, Osteoporosis, Nano-carriers.

INTRODUCTION:

Cancer is a significant cause of mortality globally, responsible for nearly 10 million deaths in 2020, representing approximately one in six deaths. The World Health Organization (WHO) states that the most prevalent cancers are breast, lung, colorectal and prostate cancer¹. The most frequent solid malignant tumor is breast cancer, impacting 2.26 million females globally, with approximately 685,000 deaths reported each year. In India, there were 178,361 newly discovered cases of breast cancer in all age groups of women². Breast cancer affects women worldwide, occurring at any age after puberty, with incidence increasing in later years.

One of the main risk factors for breast cancer for women is that between 0.5 and 1% of men will also receive a diagnosis. According to IARC projections, the incidence of breast cancer will grow by more than one-third by 2040, accounting for over 3 million new cases yearly, while mortality will rise by more than half, resulting in over 1 million deaths annually. The Global Breast Cancer Initiative aims to enhance the availability of early detection and comprehensive management of breast cancer.

Breast cancer is a diverse or heterogeneous disease, with tumors categorized depending on histology and molecular subtypes; invasive and non-invasive forms of the disease are classified by their histological features, with the former involving ducts and lobules and the latter affecting only lobules and ducts. The molecular subtypes of breast cancer, as detailed in Table 1. 50% of cases of breast cancer are of luminal type A, which includes ER+/PR+ (Estrogen receptor positive and or Progesterone receptor positive) breast cancer. Among these, 60 to 80% of these are estrogen receptor-positive invasive breast cancers in postmenopausal women³.

Fig. 1: Mechanism action of aromatase inhibitors and tamoxifen (SERM)

The current study addresses the drawbacks of breast cancer therapies, which are designed to treat breast cancer by improving the therapeutic effect of the drug through combination therapy with synthetic or natural drugs using a nanotechnology approach, avoiding drug-induced side effects, and reducing the likelihood of drug resistance. Additionally, in-silico studies, such as molecular docking, ADMET, and simulation studies, are among the most effective strategies for selecting appropriate drugs by evaluating and comparing their mechanisms of action. Emphasized the adverse effects in postmenopausal breast cancer women on bone health. As of now, no study including all challenges and promising approaches related to breast cancer in one study has been covered for literature review.

Treatment:

Surgical therapy such as lumpectomy and mastectomy, chemotherapy, radiation, and targeted and endocrine therapy are currently the mainstay of breast cancer treatment. Surgery is commonly followed by adjuvant treatment aimed at preventing and eliminating recurrence and metastasis that may develop post-surgery. However, adjuvant therapy, such as endocrine or radiation therapy, as well as chemotherapy, is preferred for the subtype of breast cancer⁴. Hormonal or endocrine therapy is the mainstay in estrogen-positive breast cancer (ER+ BC); this approach includes the use of selective estrogen modulators (SERMs) and aromatase inhibitors (AIs), as detailed in Table 2. The target is estrogen receptors, which are categorized into two following subtypes: α (alpha ER) and β (beta ER). The ERα is associated with hallmarks of various cancers and sustained cell proliferation, whereas ERβ is thought to counteract the cancer-promoting effects of ERα⁵. Tamoxifen is standard treatment for both premenopausal and postmenopausal breast cancer; cause breast cancer or tumor inhibition by blocking estrogen binding to ER competitively, thus interfering estrogen utility for breast cancer growth. However, it enhances the risk of endometrial carcinoma and thromboembolic disease, which jeopardizes its therapeutic effect in breast cancer⁶. Therefore, an alternative approach of inhibiting estrogen production by targeting the aromatase enzyme, which is essential in estrogen biosynthesis, has been utilized for the effective treatment of breast cancer. Aromatase inhibitors are generally preferred over tamoxifen because they are linked to decreased mortality and recurrence rates of breast cancer^7,8. Aromatase inhibitors prevent the conversion of androgen to estrogen-inhibiting aromatase enzyme, thus preventing estrogen-positive tumours of estrogen-induced growth, as shown in Fig. 1. The mainstay adjuvant treatment for postmenopausal women with localised or early-stage breast cancer that is estrogen positive is aromatase inhibitors (AIs)⁷. These inhibitors are typically prescribed for a minimum of five years, with some treatments extending for ten years.

Table 1: Molecular subtypes of Breast cancer

Sr. No.	Subtypes of breast cancer	Clinicopathologic definition	Survival rate	Type of Therapy	Refe rences
1	Luminal A	Hormone Receptor Positive (HR+) Estrogen Receptor Positive (ER+) Progesterone receptor positive (PR+) Slow growing and less aggressive	50%	Hormone Therapy	4, 9
2	Luminal B	Estrogen receptor (ER+) HER 2+ But Progesterone Negative (PR-) High expression of HER2+	20%	Hormone and anti-VGFR therapy	4, 10
3	Human Epidermal growth factor receptor 2  (HER 2+ )	Hormone receptor negative (HR-) Human epidermal growth factor receptor 2 positive (HER 2+) Dangerous and rapidly growing	15%	Anti-HER2+, Chemotherapy	11,12
4	Triple-negative Cancer	HR- HER2- Most aggressive tumours that arise from basal cell	15%	Combination of surgery, radiotherapy and chemotherapy	4,13,14

ER-positive metastatic breast cancer may either exhibit resistance to hormonal or endocrine therapy over time by activating alternate signalling pathways that support cell survival and proliferation, or it might show primary resistance to the treatment, known as de novo resistance. Resistance to anti-estrogenic therapy is caused by multiple mechanisms, such as loss or down-regulation of ER expression, ligand-independent activation of the receptors because of mutations in the ESR1 gene and epigenetic modification of ER and its co-regulators such as phosphorylation, methylation and ubiquitination. Another critical component of this resistance is an imbalance in ER co-regulators¹⁵.

Table 2- Hormonal breast cancer treatments with their adverse effects^16,17

Hormonal therapy	Medications	Mechanism of Actions	Adverse Effects of Medicines
Selective estrogen receptor modulators (SERMs)	Tamoxifen, Raloxifen, Toremifene	Prevents estrogen Binding to its receptor.	Risk of thrombotic events, Hypertension, Arthralgia, Edema, Flushing, Hot flashes, Amenorrhea, Changes in vaginal discharge/ dryness
Aromatase inhibitors (AI)	Anastrozole Letrozole Exemestane	Works by inhibiting the action of the enzyme aromatase, which converts androgen to estrogen	Osteoporosis, Arthralgia, Muscle and joint pain Risk of cardiovascular disease, Loss of bone mineral density, Hot flashes
Selective Estrogen Receptor Downregulator (SERD)	Fulvestrant	Eliminate the ER expression by making fewer receptors available for binding to ER.	Allergic reaction, which may cause rash, low blood pressure, wheezing, shortness of breath, and swelling of the face or throat.
Human epidermal growth receptor 2 blockers (HER 2)	Trastuzumab Pertuzumab Adotrastuzumab ematansine Lapatinib	Inhibit HER2 mediated signaling cascade.	Cardiomyopathy, cardiovascular toxicity, Hepatotoxicity
Cytotoxic Agents	Doxorubicin Cisplatin Paclitaxel Cyclophosphamide	Interfering with DNA synthesis or producing chemical damage to DNA.	Fatigue, Hair loss, Heart problem, Loss of appetite Nausea and vomiting, Mouth sores

Risk Factors:

Breast cancer development may be influenced by various risk factors, including genetic mutations, specifically those affecting the BRCA1 and BRCA 2 tumor suppressor genes. Genetic or heredity factors contribute to less than 10% of breast cancer.  

Fig 2: Risk Factors of Breast Cancer and Strategies for Breast Cancer Therapy

cases¹⁸. Also, lifestyle, including diet, smoking and alcohol consumption, as well as obesity, and environmental factors, including exposure to radiation and chemicals, increase the possibility of developing breast cancer. Reproductive history, such as age at first pregnancy and advanced menopause^13,19 (Fig. 2). The most significant increase in risk of breast cancer in postmenopausal women is positively correlated with estrogen levels and free estradiol. Because obesity increases aromatase activity in adipose tissue, circulating estradiol levels in obese postmenopausal women are approximately twice as high as in normal-weight women, increasing their risk of breast cancer²⁰. The decrease in circulating estrogen levels in postmenopausal women results in a number of unpleasant symptoms, such as osteoporosis, mood swings, hot flashes, and urogenital atrophy. For these symptoms, especially osteoporosis, hormone replacement therapy (HRT) works effectively. However, prolonged exposure to these hormones can increase the risk of developing hormone-dependent breast cancer²¹. An essential enzyme in the process of aromatisation, which catalyses the transformation of androgenic steroids into estrogen, is aromatase.

Elevated estrogen levels, as well as deregulation of aromatase, have been connected to a number of cancers, including breast cancer. Age at conception affects how dynamic estrogen levels are maintained²². The most potent estrogen produced in the ovaries, 17-β estradiol, circulates and affects distant target organs in an endocrine manner in postmenopausal women. Obesity in postmenopausal women has an elevated breast cancer risk due to circulating estradiol levels that are nearly double that of women of average or typical weight⁵.

Challenges And Promising Strategies:

Endocrine therapy-related osteoporosis or bone loss in breast cancer women's:

Although advancements in early detection and treatment have been made, a diagnosis of breast cancer continues to be significantly linked with both morbidity and mortality. The benefits of adjuvant endocrine therapy for cancer have been accompanied by additional potential toxicities related to treatment, such as osteoporosis, joint and muscle pain, hot flashes, night sweats, and other adverse reactions. As survival rates for breast cancer have steadily improved over recent decades, there is growing interest in investigating the long-term consequences of cancer therapy, like fractures and bone loss. Aromatase inhibitors are linked to a higher risk of bone loss and fractures compared to tamoxifen²³. Breast cancer and its treatments may exacerbate this risk by impacting bone structure and hormone production or by preventing androgens from being converted to estrogen, which causes cancer treatment-induced- bone loss.

Biomarkers in postmenopausal Osteoporosis:

Estrogen (ER) is a crucial regulator of bone turnover. Estrogen is vital for bone development and maintenance; a deficiency in estrogen leads to an imbalance between bone resorption and formation. Also, ER production plays a crucial role in the development of breast tumors. Osteoporosis is a condition marked by an elevated risk of bone fractures and reduced bone mineral density (BMD) associated with decreased estrogen levels. It is common in about one in three menopausal women and elderly patients. Postmenopausal status, characterized by very low ER levels, results in significantly increased bone resorption and a continuous reduction in BMD, ultimately raising the risk of fractures^24,25.

One important cytokine in the tumor necrosis factor (TNF) family, which is encoded by 11 genes, is the receptor activator of nuclear factor kappa beta ligand (RANKL). Research has demonstrated that RANK-transgenic mice develop breast cancer more quickly and that increased RANKL expression is linked to mammary carcinogenesis in DMBA-induced animals. These results imply that RANKL is essential for the development of mammary tumors, which may provide information for future studies aimed at targeting RANKL for the treatment of hormone receptor-positive breast cancer. Furthermore, RANKL plays a critical role in human physiology by regulating the growth and activation of osteoclasts, the cells that break down bone. To preserve bone and skeletal integrity, osteoclasts initiate a series of actions that eliminate and replace low-quality bone with new bone. According to reports, RANKL stimulates osteoclastogenesis when overexpressed, leading to excessive bone resorption and subsequent loss of bone integrity. Interestingly, both breast growth and breast cancer have been linked to the RANKL/RANK pathway²⁶. Furthermore, bone growth, skeletal homeostasis, and bone regeneration and repair are all significantly impacted by the Wnt signaling pathway. It blocks osteoblast differentiation and proliferation; thus, Wnt signaling is a potential target for osteoporosis treatment²⁷.

Recommended Treatment for osteoporosis induced by breast cancer therapy:

Anti-osteoporotic treatments such as bisphosphonates are the primary treatment for women with an increased risk of fracture. They must be used in conjunction with vitamin D supplements if their bone mineral density (BMD) is less than -2.5. Also, Zoledronic acid and Denosumab (4mg and 60mg, respectively, every six months) have been shown to prevent skeletal-related adverse effects in women with BC24 significantly. To treat postmenopausal osteoporosis, raloxifene, a selective estrogen receptor modulator, binds to ERα and ERβ and exhibits either tissue-specific agonistic or antagonistic actions at these receptors. According to studies, people with breast cancer who experience letrozole-induced bone loss may benefit from using raloxifene in addition to letrozole. Through the RANK-RANKL-OPG axis, this combination not only regulates osteoclastogenesis but also enhances osteoblastogenesis through the Wnt signaling pathway. As a result, raloxifene may help prevent and treat letrozole-induced osteoporosis^17,28.

Natural sources in breast cancer treatments:

Natural items have been a significant source of anticancer medications; about 60% of anticancer drugs (paclitaxel, docetaxel, vinblastine, vincristine, and etoposide etc.) are derived from natural sources.⁴. Recent research has examined natural therapies for treating breast cancer and postmenopausal symptoms, focusing on the side effects, toxicity, and resistance associated with long-term endocrine treatment. The structural similarity of phytoestrogens, polyphenolic, and non-steroidal substances to mammalian estrogen makes them particularly interesting. Among these, lignans, coumestans, stilbenes, and isoflavonoids have demonstrated estrogen-mediated actions²⁹. According to research, eating a diet high in phytoestrogens (PEs) may help prevent diseases linked to estrogen, including cardiovascular disorders, osteoporosis, and malignancies of the breast and prostate.  This is attributed to their well-known properties, including antioxidant, anti-osteoporosis, anti-cancer, and anti-atherosclerosis effects. Numerous phytochemicals, such as lignans, quercetin, resveratrol, β-elemene, carotenoids, curcumin, daidzein, epigallocatechin gallate, γ-tocotrienol, genistein, hesperetin, hesperidin, kaempferol, and tangeritin, have shown anticancer effect against breast cancer as well as anti-osteoporosis effect^14,30,31.

Nanocarriers:

Conventional therapies against breast cancer include various chemotherapeutic agents with different combinations, and hormonal therapies possess off-site side effects. The pharmacokinetic issues of drugs like solubility, encapsulation, and some other factors and hence, the nanotechnology approach addresses advantages over conventional treatment in breast cancer³². Nanoparticulate drug delivery systems have the potential to improve the oral delivery of several anticancer drugs, enhancing their safety profiles and therapeutic efficacy. Nanocrystals, lipid nanocapsules, drug-polymer conjugates, polymeric nanoparticles³³, polymeric micelles, SEDDS, and lipid-based nanocarriers are various formulation strategies³⁴. Nanoparticles carrying anticancer drugs hold significant potential for effectively targeting and eradicating breast cancer stem cells. Nanoparticles enhance or improve the oral bioavailability of drugs by preventing the first-pass metabolism and increasing the uptake of drugs, with increasing drug encapsulation and enhancing solubilization capacity.⁴

Combination Therapy:

In an effort to overcome the toxicological issues with monotherapy, cancer treatment plans have recently adopted a combinatorial approach progressively. Treatment for a variety of malignancies, including breast cancer, has shown encouraging outcomes when synthetic chemotherapeutic drugs are combined with herbal bioactive compounds that have anticancer characteristics. Either additively or synergistically, this combination can increase the efficacy of monotherapy³⁵. As previously stated, the cornerstone of treatment for ER+ breast cancer is hormone therapy, often known as endocrine therapy. Even while endocrine treatment is beneficial, cancer patients usually suffer from severe side effects such as mood swings, sleep disruptions, hot flashes, and depressed symptoms, which can lower their quality of life. These symptoms can be treated with estrogen and/or progestin-based hormone replacement therapy (HRT). HRT is inappropriate for women with breast cancer, as it may promote the growth of breast cancer cells. As a result, many people choose plant-based substitutes to lessen the psychosocial and neurovegetative side effects of hormone therapy³⁶.

Combination therapy (dual drug therapy) uses drugs that possess various mechanisms, resulting in a reduction of resistance to treatment. It provides therapeutic benefits while reducing or preventing recurrence, resistance, and adverse effects, thereby ensuring patients' better quality of life. For instance, a significant concern with aromatase inhibitors is their impact on bone health. Hence, the combination of aromatase inhibitors with natural or synthetic drugs may reduce the dose of each drug and give additive or synergistic effects toward breast cancer cells, subsequently minimizing the off-target toxicity of medicine.

Drug targeting to tumor cells via ligands:

Strategies that target the active site using affinity ligands on nanoparticle surfaces have been developed to enhance drug specificity and increase uptake by target cells. Some examples include the CD44-targeting site on tumor cells, which makes hyaluronic acid-modified nanocarriers promising for treating breast cancer^37,38. Various drugs, including paclitaxel, doxorubicin, Adriamycin, vincristine sulfate, resveratrol, and raloxifene, and other studies have highlighted the use of folic acid-modified albumin nanocarriers. Albumin nanoparticles can increase therapeutic solubility, protect the molecule from degradation, and improve tumor cell targeting^39–41. Furthermore, boronic acid-targeted albumin-shell oily-core nanocapsules containing exemestane and hesperetin, two aromatase inhibitors, were created in a study by Mohamed G. et al. This formulation demonstrated synergistic effects, reduced dosage requirements, and helped mitigate one of the significant side effects, such as bone loss associated with hormonal therapy⁴².

In-silico studies:

In silico methods have become indispensable in modern drug discovery, offering a practical, cost-efficient approach to drug design and optimization. Techniques such as molecular docking, ADMET analysis, and computational simulations play a crucial role in predicting the behavior of drug candidates. Molecular docking helps assess interactions between small molecules and biological targets, while ADMET analysis provides insight into the potential of drugs' absorption, distribution, metabolism, excretion, and toxicity. Additionally, simulation studies enable researchers to observe dynamic molecular interactions and biological processes in silico. By integrating these computational tools, researchers can streamline the drug development process, select the most promising candidates, and improve the overall efficiency of the drug discovery pipeline.^43,44.

CONCLUSION:

Hormonal therapy is used in metastasis as well as localized or early breast cancer. Additionally, the emergence of side effects and drug resistance, as well as recurrence, have become challenges that persist in the treatment of breast cancer. Numerous natural phytochemicals, including phytoestrogens, exhibit potential benefits for both treating breast cancer and preventing postmenopausal symptoms while also mitigating the drawbacks of synthetic drugs. Evidence suggests that monotherapy is often insufficient due to its toxicity, development of resistance, and recurrence. Therefore, combining treatments with nanomedicine has become a promising approach, providing fewer side effects and reduced risk of drug resistance. It's a challenging tool for breast cancer treatment to prevent metastasis of breast cancer. Anticancer drugs are delivered to tumor cells via ligand-receptor interactions, a promising strategy for enhancing therapeutic efficacy while minimizing off-target side effects (as shown in in silico studies). pH-responsive, dual-responsive nanoparticle-based drug delivery is also a promising tool in breast cancer therapy.

REFERENCES:

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. A Cancer Journal for Clinicians 2021; 71(3): 209-249. doi:10.3322/caac.21660

2. Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66: 15-23. doi:10.1016/j.breast.2022.08.010

3. García-Sánchez J, Mafla-España MA, Torregrosa MD, Cauli O. Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study. Breast. 2022; 66: 310-316. doi:10.1016/j.breast.2022.11.007

4. Yap KM, Sekar M, Fuloria S, et al. Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature. International Journal of Nanomedicine. 2021; 16: 7891-7941. Published 2021 Dec 2. doi:10.2147/IJN.S328135

5. van Dyk L, Verhoog NJD, Louw A. Combinatorial treatments of tamoxifen and SM6Met, an extract from Cyclopia subternata Vogel, are superior to either treatment alone in MCF-7 cells. Frontiers in Pharmacology. 2022; 13: 1017690. Published 2022 Sep 22. doi:10.3389/fphar.2022.1017690

6. Choi SH, Kim KE, Park Y, et al. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. Breast. 2020; 54: 25-30. doi:10.1016/j.breast.2020.08.003

7. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. International Journal of Clinical Practice. 2007; 61(12): 2051-2063. doi:10.1111/j.1742-1241.2007.01587.x

8. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone. 2007; 40(1): 205-210. doi:10.1016/j.bone.2006.06.027

9. Eissa AG, Barrow D, Gee J, Powell LE, Foster PA, Simons C. 4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors. European Journal of Medicinal Chemistry. 2022; 240: 114569. doi:10.1016/j.ejmech.2022.114569

10. Moudgil A, Salve R, Gajbhiye V, Chaudhari BP. Challenges and emerging strategies for next generation liposomal based drug delivery: An account of the breast cancer conundrum. Chemistry and Physics of Lipids. 2023; 250: 105258. doi:10.1016/j.chemphyslip.2022.105258

11. Vieira C, Piperis MN, Sagkriotis A, Cottu P. Systemic treatment for hormone receptor-positive/ HER2-negative advanced/ metastatic breast cancer: A review of European real-world evidence studies. Critical Reviews in Oncology/ Hematology. 2022; 180: 103866. doi:10.1016/j.critrevonc.2022.103866

12. Bishoyi B, Jaiswal H, Shah Y, Dikkatwar M, Bindu R.  Early detection and Advanced Targeted Drug Therapies for HER2 positive breast cancer. Research Journal of Pharmacy and Technology. 2023; 16(5): 2205-9. doi: 10.52711/0974-360X.2023.00362

13. Wahyuni, Diantini A, Ghozali M, Sahidin I. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC). Research Journal of Pharmacy and Technology. 2022; 15(1): 409-8. doi: 10.52711/0974-360X.2022.00068

14. Dhania N, Riris IJ, Febri W, Rohmad YU, et al. Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. Research Journal of Pharmacy and Technology. 2021; 14(8): 4375-2. doi: 10.52711/0974-360X.2021.00760

15. Ferrari P, Nicolini A. Overcoming Endocrine Resistance in Breast Cancer : mTOR Inhibitors and New Drugs. Oncogenomics. Elsevier Inc.; 2019. 391–420 doi:http://dx.doi.org/10.1016/B978-0-12-811785-9.00029-6

16. Oh SH, Nam BR, Lee IS, Lee JH. Prolonged anti-bacterial activity of ion-complexed doxycycline for the treatment of osteomyelitis. European Journal of Pharmaceutics and Biopharmaceutics. 2016; 98: 67–75. doi: http://dx.doi.org/10.1016/j.ejpb.2015.11.006

17. Kalam A, Talegaonkar S, Vohora D. Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice. Molecular and Cellular Endocrinology . 2017; 440: 34-43. doi:10.1016/j.mce.2016.11.005

18. Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. International Journal of Molecular Sciences. 2023; 24(7): 6834. Published 2023 Apr 6. doi:10.3390/ijms24076834.

19. Sun YS, Zhao Z, Yang ZN, et al. Risk Factors and Preventions of Breast Cancer. International Journal of Biological Sciences. 2017; 13(11): 1387-1397. Published 2017 Nov 1. doi:10.7150/ijbs.21635

20. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011; 76(8): 812-815. doi:10.1016/j.steroids.2011.02.029

21. Khan MZI, Uzair M, Nazli A, Chen JZ. An overview on Estrogen receptors signaling and its ligands in breast cancer. European Journal of Medicinal Chemistry. 2022; 241: 114658. doi:10.1016/j.ejmech.2022.114658

22. Xu J, Cao B, Li C, Li G. The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy. Frontiers in Oncology. 2023; 13: 1218206. Published 2023 Jul 7. doi:10.3389/fonc.2023.1218206.

23. Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. Journal of Bone Oncology. 2021; 28: 100355. Published 2021 Mar 18. doi:10.1016/j.jbo.2021.100355.

24. Trémollieres FA. Trémollieres FA. Screening for osteoporosis after breast cancer: for whom, why and when. Maturitas. 2014; 79(3): 343-348. doi:10.1016/j.maturitas.2014.08.001.

25. Padmanabhan K, Paul J, Sudhakar S, Senthil Selvam P, Sathya Priya V, Veena Kirthika S. Which is more prevalent among the female population - Osteopenia or Osteoporosis? A cross sectional study. Research Journal of Pharmacy and Technology. 2019; 12(3): 1163-1168. doi: 10.5958/0974-360X.2019.00192.6

26. Muhammad A, Mada SB, Malami I, et al. Postmenopausal osteoporosis and breast cancer: The biochemical links and beneficial effects of functional foods. Biomedicine and Pharmacotherapy. 2018; 107: 571-582. doi:10.1016/j.biopha.2018.08.018

27. Gao Y, Chen N, Fu Z, Zhang Q. Progress of Wnt Signaling Pathway in Osteoporosis. Biomolecules. 2023; 13(3): 483. Published 2023 Mar 6. doi:10.3390/biom13030483

28. Vohora D, Kalam A, Leekha A, Talegaonkar S, Verma AK. Combined Raloxifene and Letrozole for Breast Cancer Patients. Archives of Medical Research. 2017; 48(6): 561-565. doi:10.1016/j.arcmed.2017.11.012

29. Goyal A, Gupta JK, Garabadu D. Phytoestrogens are emerging medicine in Prevention and Management of Cognitive deficits in Postmenopausal Women. Research Journal of Pharmacy and Technology.  2021; 14(1): 513-515. doi: 10.5958/0974-360X.2021.00093.7.

30. Ahmed HH, Aglan HA, Elsayed GH, Hafez HG, Eskander EF. Quercetin Offers Chemopreventive Potential against Breast Cancer by Targeting a Network of Signalling Pathways. Research Journal of Pharmacy and Technology. 2021; 14(5)  doi: 10.52711/0974-360X.2021.00499.

31. Ahirwar B, Ahirwar D. In vivo and in vitro investigation of cytotoxic and antitumor activities of polyphenolic leaf extract of Hibiscus sabdariffa against, breast cancer cell lines. Research Journal of Pharmacy and Technology. 2019; 13(2): 615-620. doi: 10.5958/0974-360X.2020.00116.X

32. Tanwar AK, Dhiman N, Kumar A, Jaitak V. Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach. European Journal of Medicinal Chemistry. 2021; 213: 113037. doi:10.1016/j.ejmech.2020.113037

33. Mondal R, Dey D, Maity S, Giri TK. Recent advancement of Ionic polysaccharide-based nanoparticles for Cancer therapy. Research Journal of Pharmacy and Technology. 2021; 14(2): 1122-1130. doi: 10.5958/0974-360X.2021.00202.X.

34. Sartaj A, Annu, Biswas L, et al. Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization. BioMed Research International. 2022; 2022: 6009309. Published 2022 Feb 3. doi:10.1155/2022/6009309

35. Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharmaceutical Nanotechnology. 2019; 7(1): 3-23. doi:10.2174/2211738507666190122111224

36. Poschner S, Wackerlig J, Dobusch D, et al. Actaea racemosa L. extract inhibits steroid sulfation in human breast cancer cells: Effects on androgen formation. Phytomedicine. 2020; 79: 153357. doi:10.1016/j.phymed.2020.153357

37. Fang Z, Li X, Xu Z, et al. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery.  International Journal of Nanomedicine 2019; 14: 5785-5797. Published 2019 Jul 30. doi:10.2147/IJN.S213974

38. Han NK, Shin DH, Kim JS, Weon KY, Jang CY, Kim JS. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. International Journal of Nanomedicine. 2016; 11: 1413-1425. Published 2016 Apr 5. doi:10.2147/IJN.S95850

39. Meng F, Liu F, Lan M, Zou T, Li L, Cai T, et al. Preparation and evaluation of folate-modified albumin baicalin-loaded nanoparticles for the targeted treatment of breast cancer. Journal of Drug Delivery Science and Technology 2021; 65: 102603. doi:10.1016/j.jddst.2021.102603

40. Cé R, Couto GK, Pacheco BZ, et al. Folic acid-doxorubicin polymeric nanocapsules: A promising formulation for the treatment of triple-negative breast cancer. European Journal of Pharmaceutical Sciences 2021; 165: 105943. doi:10.1016/j.ejps.2021.105943

41. Sinai Kunde S, Wairkar S. Folic acid anchored urchin-like raloxifene nanoparticles for receptor targeting in breast cancer: Synthesis, optimisation and in vitro biological evaluation.  International Journal of Pharmaceutics 2022; 623: 121926. doi:10.1016/j.ijpharm.2022.121926

42. Gaber M, Hany M, Mokhtar S, Helmy MW, Elkodairy KA, Elzoghby AO. Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. Materials Science and Engineering: C. 2019; 105: 110099. doi:10.1016/j.msec.2019.110099

43. Salsa LA, Tri W, Suko H, Bambang TP. QSAR of Acyl pinostrobin derivatives as Anti-breast cancer against HER-2 receptor and their ADMET properties based on in silico Study. Research Journal of Pharmacy and Technology. 2022; 15(10): 4641-8. doi: 10.52711/0974-360X.2022.00779

44. Jainab NH, Mohan MK. In Silico Molecular Docking Studies on the Chemical Constituents of Clerodendrum phlomidis for its Cytotoxic Potential against Breast Cancer Markers. Research Journal of Pharmacy and Technology. 2018; 11(4): 1612-1618. doi: 10.5958/0974-360X.2018.00300.1

Received on 11.02.2025      Revised on 14.08.2025

Accepted on 25.11.2025 Published on 16.03.2026

Available online from March 18, 2026

Research J. Pharmacy and Technology. 2026;19(3):1383-1389.

DOI: 10.52711/0974-360X.2026.00199

© RJPT All right reserved

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.